EUVIMEDEUVIMED entdecken
Crossref

Linagliptin exacerbates heart failure due to energy deficiency via downregulation of glucose utilization and absorption in a mouse model

Aya Shiraki, Jun-Ichi Oyama, Takahiko Shimizu, Koichi Node

European Journal of Pharmacology · 2023

DOI: 10.1016/j.ejphar.2023.175673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2023. Verfasst von Aya Shiraki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Saga University, Japan. Electronic address: nakajiay@cc.saga-u.ac.jp. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Heart Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Saga University, Nihon Medi-Physics, Boehringer Ingelheim Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Use of dipeptidyl peptidase-4 (DPP4) inhibitor in some clinical trials might have caused heart failure (HF), leading to increased hospitalizations. The aim of the present study was to determine whether linagliptin has any effect on chronic dilated HF, and its underlying mechanisms. Physiologic and pathologic studies were conducted on heart/muscle-specific manganese superoxide dismutase-deficient mice, which exhibited dilated cardiomyopathy, and were randomized to receive a low dose (1 mg/kg, HF-L group) or high dose (10 mg/kg, HF-H group) mixed with food, or normal food (HF group), for 8 weeks. Linagliptin increased mortality and heart/body weight ratio in mice with HF. Cardiac contractility and fibrosis worsened, whereas hepatic glycogen content and individual carbohydrate consumption decreased significantly in the HF-H group, when compared with the HF control group. Therefore, we performed a complementary experiment by supplementing glucose to the mice treated with high-dose linagliptin (HF-HG group). Adequate glucose supplementation reduced heart/body weight ratio and cardiac fibrosis, and improved cardiac contractility, without changing mortality. Following oral administration of 13C glucose, the respiratory 13C decreased in the HF-H and HF-HG groups, when compared with that in the HF group; the fecal 13C increased, suggesting that linagliptin inhibited glucose absorbance in the intestine. In addition, the expression of GLUT2, a glucose transporter was downregulated in the small intestine. Linagliptin treatment exacerbated HF, which increased mortality, cardiac function, and fibrosis. DPP4 inhibitors might boost cardiac cachexia and exacerbate HF, at least in part, through the modification of glucose utilization and absorption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dipeptidyl-Peptidase IV InhibitorsHeart FailureAnimalsMiceBody WeightDisease Models, AnimalDown-RegulationFibrosisGlucoseHypoglycemic AgentsLinagliptin

Stichwörter der Autor:innen

DPP4 inhibitorGLP-1GlucoseHeart failureMalabsorptionMetabolism

Substanzen

Dipeptidyl-Peptidase IV InhibitorsGlucoseHypoglycemic AgentsLinagliptin

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Saga University, Japan. Electronic address: nakajiay@cc.saga-u.ac.jp.
  • Department of Cardiovascular Medicine, Saga University, Japan.
  • Aging Stress Response Research Project Team, National Center for Geriatrics and Gerontology, Japan.

Förderung

  • Saga University
  • Nihon Medi-Physics
  • Boehringer Ingelheim Japan

Zitieren

APA

Shiraki, A., Oyama, J. I., Shimizu, T., & Node, K. (2023). Linagliptin exacerbates heart failure due to energy deficiency via downregulation of glucose utilization and absorption in a mouse model. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2023.175673

Vancouver

Shiraki A, Oyama JI, Shimizu T, Node K. Linagliptin exacerbates heart failure due to energy deficiency via downregulation of glucose utilization and absorption in a mouse model. European Journal of Pharmacology. 2023. doi:10.1016/j.ejphar.2023.175673

BibTeX
@article{Shiraki2023,
  author = {Shiraki, Aya and Oyama, Jun-Ichi and Shimizu, Takahiko and Node, Koichi},
  title = {Linagliptin exacerbates heart failure due to energy deficiency via downregulation of glucose utilization and absorption in a mouse model},
  journal = {European Journal of Pharmacology},
  year = {2023},
  doi = {10.1016/j.ejphar.2023.175673}
}
Kostenlos starten →